Breaking Down Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) is a growth story or a value trap? With Q3 2025 operating revenue hitting RMB 320 million (up 10.61% YoY) and trailing twelve-month revenue at RMB 1.30 billion (a 25.64% rise), backed by a five-year streak of double-digit CAGRs and exports accounting for over 40% of sales, the top line grabs attention; profitability reinforces the case-Q3 net profit attributable to shareholders reached RMB 94.85 million (up 50.48% YoY), TTM net profit margin is about 25.2% with EPS at RMB 0.77 and ROE at 14.61%; balance-sheet metrics show total assets of RMB 2.58 billion, equity of RMB 1.88 billion and a conservative debt-to-equity ratio of 0.37 while liquidity is robust-cash and equivalents of RMB 531 million (up 70.38% YoY), a current ratio ~2.5 and quick ratio ~1.8-and investors can weigh valuation signals (P/E 26.07, market cap ~RMB 8.86 billion, dividend yield 1.04%) alongside risks like raw material swings, regulatory shifts, currency volatility and competition as you dig into the full breakdown below.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Revenue Analysis

• Q3 2025 operating revenue: RMB 320 million (YoY +10.61%).
• Trailing twelve months (TTM) revenue: RMB 1.30 billion (up 25.64% YoY).
• FY 2024 revenue: RMB 1.15 billion (growth of 32.64% vs. FY 2023).
• Five‑year performance: consistent double‑digit CAGR.
• Exports: >40% of total revenue, reflecting a significant international footprint.
• Workforce: 988 employees; revenue per employee ≈ RMB 1.32 million.

• Growth drivers: expanding export channels (now >40% of sales), scale benefits from rising TTM revenue, and sustained product demand supporting multi‑year double‑digit CAGRs.
• Efficiency metric: RMB 1.32 million revenue per employee signals relatively high labor productivity for the sector.
• Momentum indicators: Q3 2025 growth (10.61% YoY) plus a TTM increase of 25.64% suggests acceleration versus trailing annual figures, consistent with prior-year 32.64% expansion in 2024.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Profitability Metrics

• Q3 2025 net profit attributable to shareholders: RMB 94.85 million (up 50.48% YoY).
• 2024 net profit attributable to parent company: RMB 246.00 million (up 27.26% vs. 2023).
• Net profit (2023, implied): RMB 193.41 million (derived from 2024 growth of 27.26%).
• Trailing twelve months (TTM) net profit margin: ~25.2%.
• Company profit margin has held around ~22% over the past two years (2023-2024).
• TTM EPS: RMB 0.77 (vs. RMB 0.60 in 2023).
• TTM Return on Equity (ROE): ~14.61%.

• EPS acceleration: TTM EPS of RMB 0.77 vs RMB 0.60 in 2023 signals improved per-share profitability.
• Margin trajectory: steady ~22% in 2023-2024 with a higher TTM margin (~25.2%) suggests recent margin expansion.
• ROE of ~14.61% (TTM) indicates solid return generation relative to equity base.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Debt vs. Equity Structure

• Balance-sheet composition: equity represents ~72.87% of total assets (1.88bn / 2.58bn), liabilities ~27.13%.
• Leverage profile: debt-to-equity 0.37 signals conservative financing; company relies more on equity than debt to fund growth.
• Capital dilution: 30% increase in share capital raised equity but reduced net assets per share by 13.99% to RMB 4.47.
• Profitability vs. capital: ROE of 14.61% indicates healthy return on the enlarged equity base, improving by 3.19 ppt YoY.

• Investor implications:
  • Lower leverage reduces interest-rate and solvency risk but requires monitoring of capital allocation to ensure ROE sustains above cost of equity.
  • Dilution lowered per-share book value; prospective investors should weigh EPS and dividend outlook against growth funded through equity issuance.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Liquidity and Solvency

• Cash and cash equivalents: RMB 531 million in Q3 2025 - up 70.38% year-on-year.
• Current ratio: ~2.5, indicating ample coverage of current liabilities by current assets.
• Quick ratio: ~1.8, showing sufficient liquid assets to meet immediate obligations.
• Net operating cash flow (H1 2025): RMB 182 million - up 82.9% year-on-year.
• Interest coverage ratio: 12, reflecting a strong ability to service interest expenses.

• Implications for short-term resilience: current and quick ratios above commonly accepted safety thresholds (1.0 and 1.5 respectively) support operational flexibility and reduced refinancing risk.
• Cash generation trajectory: an 82.9% increase in operating cash flow (H1 2025) combined with a 70.38% rise in cash balances suggests improving working capital management and profitability conversion to cash.
• Debt servicing: an interest coverage ratio of 12 provides a comfortable buffer for meeting finance costs, lowering solvency-related investor concerns.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Valuation Analysis

• P/E (trailing): 26.07
• Forward P/E: 24.56
• Earnings yield: ~3.8%
• Dividend yield: 1.04% (Ex-dividend: 2025-12-12)
• Market cap: ~RMB 8.86 billion
• Beta: 0.48
• 52-week range: RMB 11.56 - RMB 23.68

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) Risk Factors

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) operates in a margin-sensitive, regulation-heavy segment of the functional food ingredient and biotechnology market. Investors should weigh several concentrated risk categories that can materially affect revenue, gross margin and cash flow.

• Raw material price volatility: key inputs (amino acids, botanical extracts, fermentation feedstocks) have historically experienced large swings; a 20-40% increase in raw material costs can compress gross margins materially in the near term.
• Regulatory risk: domestic GMP, food-safety, export/ import certificates (e.g., CFDA/NMPA-related approvals) and foreign market approvals can introduce delays or require reformulation, increasing compliance costs and time-to-market.
• Currency exposure: export revenue denominated in USD/EUR/JPY subjects the company to RMB exchange-rate moves; a 5-10% RMB appreciation vs. USD can reduce reported RMB revenues from overseas sales and lower operating margins unless hedged.
• Competitive pressure: the functional ingredient sector features large global ingredient players and low-cost Chinese competitors; sustained price competition can erode ASPs (average selling prices) and market share.
• Supply chain disruption: single-source suppliers, logistic bottlenecks or port congestion can delay shipments and raise working capital requirements.
• Macroeconomic sensitivity: discretionary consumer demand for supplements and fortified products typically falls in recessions, reducing downstream order volumes.

Quantitative sensitivity scenarios (illustrative) show potential impacts on operating profit under common stressors:

• Operational concentration: production interruptions at any major facility can have outsized impacts given the company's scale relative to certain product lines.
• Customer concentration: loss or order reduction from a top-tier customer could reduce annual revenue by a high-single-digit to low-double-digit percentage depending on the product mix.
• Price pass-through ability: the firm's capacity to raise prices when inputs rise is constrained by competitive dynamics and contract terms, limiting margin recovery.

Governance and financial-position considerations relevant to risk management include working-capital cushions, hedging policies, supplier diversification and R&D/regulatory-expenditure budgets. For more context on shareholder composition and recent trading behavior, see: Exploring Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Investor Profile: Who's Buying and Why?

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Growth Opportunities

• International expansion - prioritize regulated high-value markets in Europe and North America where demand for clinically-backed functional ingredients and clean-label solutions is growing.
• New product lines - target personalized nutrition, immune-support blends, and plant-based fermentation ingredients aligned with consumer health trends.
• R&D investment - accelerate strain development, stability technologies and clinical validation to enable premium pricing and partner licensing.
• Strategic partnerships - co-development and supply agreements with global food & beverage and supplement manufacturers to scale volumes and secure multi-year revenues.
• Online channel enhancement - direct-to-consumer (DTC) and B2B e-commerce to increase margins and broaden geographic reach.
• Sustainability implementation - adopt carbon/energy efficiency and sustainable sourcing to meet procurement criteria of large Western customers.

• Key execution metrics to monitor: international revenue mix (% of total), gross margin expansion from product mix, R&D spend as % of revenue (target 3-6% to drive innovation), and online channel contribution to sales.
• Near-term operational priorities: regulatory approvals (EFSA/FDA pathways where relevant), scale-up of GMP facilities for export, and IP protection for proprietary strains/processes.